Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe

Diabetes Mellitus, Type 2 Clinical Trial

— DiaKidZ  

Official title:

Kidney Fat in Type 2 Diabetes & Diabetic Kidney Disease and the Effects of Ezetimibe: A Cross-Sectional Study and Randomized, Placebo-Controlled Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04589351
• Other study ID #: 16032020
• Secondary ID: 2020-001155-40
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 1, 2020
• Est. completion date: May 2022

Study information

• Verified date: January 2022
• Source: Steno Diabetes Center Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, we seek to explore the importance of fat accumulation in the kidneys in relation to diabetic kidney disease (DKD). To do this, we conduct an intervention trial in individuals with type 2 diabetes (T2D) and DKD where we investigate whether the inhibition of intestinal cholesterol absorption with ezetimibe affects albuminuria (a strong risk factor for diabetic complications) and kidney fat accumulation. At the same time and to confirm that kidney fat accumulation is, in fact, abnormal in T2D and DKD, we conduct a cross-sectional study in which we compare kidney fat accumulation in participants at baseline from the intervention trial with a group of individuals with T2D and no DKD and a group of healthy individuals.

Description:

Objective: 1. To compare cross-sectionally the fractions of kidney lipid between controls, individuals with type 2 diabetes and no diabetic kidney disease and individuals with type 2 diabetes and non-severe diabetic kidney disease. 2. To assess by intervention trial whether ezetimibe reduces albuminuria and kidney parenchymal triglyceride fraction in individuals with type 2 diabetes and non-severe diabetic kidney disease. Design: 1. Cross-sectional study on 30 controls, 30 individuals with type 2 diabetes and no diabetic kidney disease and 60 individuals with type 2 diabetes and non-severe diabetic kidney disease. 2. Single-center, randomized, double-blinded, placebo-controlled and parallel intervention trial in 60 individuals with type 2 diabetes and non-severe diabetic kidney disease Comparative treatment regime: Ezetimibe 10mg per day versus placebo for 16 weeks Primary endpoint in cross-sectional study: - Kidney parenchymal triglyceride fraction (estimated by magnetic resonance spectroscopy) Primary endpoint in intervention trial: - Urinary albumin creatinine ratio Secondary endpoint in intervention trial: • Kidney parenchymal triglyceride fraction (estimated by magnetic resonance spectroscopy) Main eligibility criteria for control group (cross-sectional study alone): • Age 40-75 years • No diabetes mellitus • No kidney disease or urinary albumin creatinine ratio ≥ 30mg/g • No contraindication to examination by magnetic resonance Main eligibility criteria for group of individuals with type 2 diabetes and no diabetic kidney disease (cross-sectional study alone): • Age 40-75 years - Type 2 diabetes - No kidney disease or urinary albumin creatinine ratio ≥ 30mg/g - No contraindication to examination by magnetic resonance Main eligibility criteria for group of individuals with type 2 diabetes and non-severe diabetic kidney disease (intervention trial): • Age 40-75 years - Type 2 diabetes - Estimated glomerular filtration rate ≥30ml/min/1,73m2 - Urinary albumin creatinine ratio ≥ 30mg/g - No contraindication to examination by magnetic resonance Recruitment - Controls are recruited via announcements on relevant websites and, if necessary, in newspapers - Individuals with type 2 diabetes are primarily recruited from the ambulatory at Steno Diabetes Center Copenhagen

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: May 2022
• Est. primary completion date: May 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion criteria for the intervention trial

• Age = 40 and = 75 years
• T2D (World Health Organization criteria)
• eGFR = 30ml/min/1,73m2 at screening
• Persistent UACR = 30mg/g (in more than two out of three valid measurements over a minimum of three months)
• LDL > 1.5mmol/L at screening
• Ability to communicate with the investigator and give informed consent Exclusion criteria for the intervention trial
• Chronic kidney disease primarily ascribed to other causes than diabetes
• Acute kidney disease within 3 months
• No UACR = 3000mg/g in history
• Current or recent (within 3 months) treatment with ezetimibe
• Initiation or adjustment in dosage within 1 month of an angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), glucagon-like peptide-1 receptor (GLP-1RA) agonists, sodium-glucose cotransporter 2 (SGLT-2) inhibitors or anti-dyslipidemia drug, e.g. a statin
• Any contraindication to MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination, claustrophobia or body size not compatible with the scanner)
• Intolerance to trial drug components
• Any previous major organ transplantation
• Elective major surgery during the trial
• Pregnancy, planned pregnancy or breastfeeding during the trial
• Insufficient contraception during the trial in women of childbearing potential
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Any surgical or medical condition which can be expected to significantly alter the absorption of the trial drug (e.g. major gastrointestinal tract surgery or inflammatory bowel disease)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the trial
• Any reason for suspecting a considerable lack of compliance to the trial

Inclusion criteria for the control group (cross-sectional study alone):

• Age = 40 and = 75 years
• eGFR =60ml/min/1,73m2 at screening
• Ability to communicate with the investigator and give informed consent

Exclusion criteria for the control group (cross-sectional study alone):

• Any major chronic disease, e.g. diabetes mellitus, chronic kidney disease, ischemic heart disease, chronic obstructive pulmonary disease (this criterium does not include conditions that may be considered risk factors for chronic diseases, e.g. essential hypertension, primary hypercholesterolemia)
• Acute kidney disease within 3 months
• History of persistent UACR = 30mg/g (in more than two out of three valid measurements over a minimum of three months including those at screening) or a previous diagnosis of micro- or macroalbuminuria
• Current or recent (within 3 months) treatment with ezetimibe
• Any contraindication to an MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination or claustrophobia)
• Any previous major organ transplantation
• Elective major surgery during the study
• Pregnancy, planned pregnancy or breastfeeding during the study
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the study
• Any reason for suspecting a considerable lack of compliance to the study Inclusion criteria for the group of participants with T2D and no DKD (cross-sectional study

alone):

• Age = 40 and = 75 years
• T2D (World Health Organization criteria)
• eGFR =60ml/min/1,73m2 at screening
• Ability to communicate with the Investigator and give informed consent Exclusion criteria for the group of participants with T2D and no DKD (cross-sectional study

alone):

• Any chronic kidney disease
• Acute kidney disease within 3 months
• History of persistent UACR = 30mg/g (in more than two out of three valid measurements over a minimum of three months including those at screening) or a previous diagnosis of micro- or macroalbuminuria
• Current or recent (within 3 months) treatment with ezetimibe
• Any contraindication to an MR-examination (e.g. magnetic foreign body that cannot easily be removed from the body prior to the examination or claustrophobia)
• Any previous major organ transplantation
• Elective major surgery during the study
• Pregnancy, planned pregnancy or breastfeeding during the study
• Severe alcohol consumption or abuse of recreational drugs
• Moderate to severe liver failure (Child Pugh 7-15)
• Recent (within 30 days or 5-half-lives, whichever is longer) or current participation in another clinical study in which an investigational medicinal product or device has been received
• Any medical condition or history thereof or any deviation from normal laboratory values that, in the opinion of the investigator, clinically contraindicates or hinders the completion of the study procedures
• Any reason for suspecting a considerable lack of compliance to the study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetic Kidney Disease
• Diabetic Nephropathies
• Kidney Diseases

Intervention

Drug:
• Ezetimibe 10mg
Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
• Placebo
Matching placebo

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Copenhagen	Gentofte	Capital Region

Sponsors (5)

Lead Sponsor

Collaborator

Steno Diabetes Center Copenhagen

Aase Handberg, professor, dr.med., Department of Clinical Biochemistry, Aalborg University Hospital, Alessia Fornoni, MD PhD, Professor of Medicine, Chief, Katz Family Division of Nephrology and Hypertension, Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark, Department of Clinical Physiology, Nuclear Medicine and PET at Rigshospitalet Glostrup, Valdemar Hansens Vej 1-23, 2600 Glostrup, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Urine metabolomic profile	Metabolomic profiling of polar and non-polar urinary metabolites	Change over 16 weeks of treatment
Other	Plasma extracellular vesicles	number, number from relevant cell types and for all extracellular vesicles the presence of fatty acid transporter proteins	Change over 16 weeks of treatment
Other	Urine extracellular vesicles	number, number from relevant cell types and for all extracellular vesicles the presence of fatty acid transporter proteins	Change over 16 weeks of treatment
Primary	Urinary albumin creatinine ratio (UACR)		Change over 16 weeks of treatment
Secondary	Magnetic resonans estimate of kidney parenchymal triglyceride fraction		Change over 16 weeks of treatment